In ₹ Crore except Per Share Latest Annual	JAGSNPHARM FY26	FERMENTA no data	AMRUTANJAN FY26	NGLFINE FY26	Peer Average
Valuation — at last close
P/E	36.09×	—	◆ 24.61×	33.51×	29.06× +24%
P/B	5.60×	—	◆ 3.85×	4.90×	4.37× +28%
EV/EBITDA	24.80×	—	◆ 18.35×	23.07×	20.71× +20%
Market Cap	₹1,547 Cr	—	₹1,425 Cr	₹1,613 Cr	₹1,519 Cr +2%
Growth
Revenue CAGR 3Y	6.66%	—	9.80%	◆ 21.68%	15.74% -58%
Revenue CAGR 5Y	8.85%	—	◆ 13.96%	—	13.96% -37%
Net Income CAGR 3Y	17.26%	—	13.29%	◆ 32.91%	23.10% -25%
Revenue YoY (latest Q)	9.28%	—	9.49%	◆ 33.57%	21.53% -57%
Net Income YoY (latest Q)	0.13%	—	-47.47%	◆ 99.09%	25.81% -99%
Profitability
EBITDA Margin	◆ 20.22%	—	15.06%	14.51%	14.79% +37%
Net Income Margin	◆ 15.00%	—	11.52%	9.61%	10.56% +42%
Return on Common Equity	◆ 16.69%	—	16.62%	15.74%	16.18% +3%
Return on Capital Employed	17.99%	—	◆ 19.28%	14.96%	17.12% +5%
Return on Assets	◆ 14.48%	—	12.45%	9.83%	11.14% +30%
Credit & Quality
Total Debt/Equity	◆ 0.00×	—	0.00×	0.33×	0.17× -100%
Interest Coverage	47.31×	—	◆ 355.72×	11.89×	183.81× -74%
Scale — latest FY
Revenue / Total Income	₹287 Cr	—	₹503 Cr	₹501 Cr	₹502 Cr -43%
Net Income	₹43.1 Cr	—	₹57.9 Cr	₹48.1 Cr	₹53 Cr -19%
Total Assets	₹317 Cr	—	₹509 Cr	₹545 Cr	₹527 Cr -40%
EPS	₹6.4	—	₹20.03	₹77.9	₹48.97 -87%
Book Value per Share	₹41.24	—	₹128.06	₹532.91	₹330.49 -88%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.